FDA inspectors continue to link equipment maintenance issues to data integrity problems, contamination events, and preventable batch failures. While maintenance activities are often carried out by Engineering, regulators consistently expect the Quality Unit (QU) to exercise meaningful oversight over this action. EU GMPs mirror this expectation, and industry frameworks like ICH Q10, highlight why this oversight matters. When the QU cannot demonstrate control, findings inevitably follow.
To meet modern expectations and stay ahead of regulatory scrutiny, the QU should focus on three essential actions.
- Control Maintenance Procedures and Ensure They Are Followed
The Quality Unit must approve and govern procedures that affect equipment reliability and product quality, including maintenance, cleaning, and sanitization instructions. These procedures must be clear, detailed, and consistently followed. Quality also needs to ensure that maintenance records are complete and accurate, even when work is performed by contractors.
While regulatory agencies do not inspect directly against ICH Q10, its principles reinforce the importance of structured, lifecycle-aware maintenance oversight within a robust pharmaceutical quality system. EU GMPs similarly emphasize maintaining equipment in a qualified, clean, and reliable state with maintenance activities recorded and reviewed. Across regulatory expectations, the theme is consistent: the QU owns the oversight, regardless of who performs the work.
- Use Maintenance Data When Making Quality Decisions
The FDA does not expect the Quality Unit to review every work order, but it does expect the QU to incorporate maintenance information when product quality could be affected. This includes reviewing equipment conditions during investigations, assessing maintenance-related deviations, considering equipment status during batch release, and incorporating maintenance trends into Annual Product Reviews (APRs) and Product Quality Reviews (PQRs).
ICH Q10 conceptually supports this approach by emphasizing ongoing monitoring of quality system performance. EU GMP aligns with this as well, requiring documented review of maintenance and cleaning activities as part of the site’s Quality Management System (QMS). When maintenance information doesn’t make its way into quality decisions, regulators often see it as a gap in oversight.
- Ensure that the Maintenance Program Actually Prevents Problems
A maintenance program is only effective if it prevents contamination, mix‑ups, and equipment malfunctions, and isn’t just responding to them. The Quality Unit is responsible for confirming that maintenance intervals, cleaning practices, and inspections are appropriate, risk‑based, and implemented as intended.
Both FDA guidance and EU GMPs stress proactive control of equipment used in production. The conceptual model in ICH Q10 reinforces this risk-based, forward-looking approach, encouraging companies to periodically evaluate whether systems are functioning effectively. In practice, this means quality leaders should look beyond documentation to ensure that the maintenance program genuinely protects product quality.
If you’re unsure whether your program would hold up to regulatory scrutiny, Lachman can help!
Maintenance oversight is one of the most commonly underestimated elements of the quality system and a frequent source of avoidable findings. Lachman can evaluate your maintenance program against regulatory expectations and industry-leading practices, identify vulnerabilities, and help you strengthen your overall system before gaps can become observations. Reach out to us at LCS@LachmanConsultants.com for a conversation!
